Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

Uraki, R; Iida, S; Halfmann, PJ; Yamayoshi, S; Hirata, Y; Iwatsuki-Horimoto, K; Kiso, M; Ito, M; Furusawa, Y; Ueki, H; Sakai-Tagawa, Y; Kuroda, M; Maemura, T; Kim, T; Mine, S; Iwamoto, N; Li, R; Liu, YA; Larson, D; Fukushi, S; Watanabe, S; Maeda, K; Wang, ZD; Ohmagari, N; Theiler, J; Fischer, W; Korber, B; Imai, M; Suzuki, T; Kawaoka, Y

Imai, M; Kawaoka, Y (通讯作者),Univ Tokyo, Inst Med Sci, Div Virol, Tokyo 1088639, Japan.;Imai, M; Kawaoka, Y (通讯作者),Natl Ctr Global Hlth & Med Res Inst, Res Ctr Global Viral Dis, Tokyo 1628655, Japan.;Suzuki, T (通讯作者),Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan.;Kawaoka, Y (通讯作者),Univ Wisconsin, Influenza Res Inst, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53711 USA.;Korber, B (通讯作者),Los Alamos Natl Lab, Theoret Biol & Biophys, Los Alamos, NM 87545 USA.;Korber, B (通讯作者),New Mexico Consortium, Los Alamos, NM 87545 USA.;Kawaoka, Y (通讯作者),Univ Tokyo, Pandem Preparedness Infect & Adv Res Ctr, Tokyo 1628655, Japan.

NATURE COMMUNICATIONS, 2023; 14 (1):

Abstract

The prevalence of the Omicron subvariant BA.2.75 rapidly increased in India and Nepal during the summer of 2022, and spread globally. However, the vir......

Full Text Link